Filter Search


Healthcare and Medical


Location Summary Deadline
Germany Conclusion Of Non-exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Maraviroc 2026-05-10
Germany Conclusion Of Non-exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Mercaptopurine 2026-05-10
Germany Conclusion Of Non-exclusive Discount Agreements According To § 130a Para. 8 Sgb V For The Mentioned Active Ingredients With The Possibility Of Conclusion Within The Framework Of The So-called Open House Procedure. 2026-05-10
Germany Conclusion Of Non-exclusive Discount Agreements According To § 130a Para. 8 Sgb V For The Mentioned Active Ingredients With The Possibility Of Conclusion Within The Framework Of The So-called Open House Procedure. 2026-05-10
Germany Conclusion Of Non-exclusive Discount Agreements According To § 130a Para. 8 Sgb V For The Mentioned Active Ingredients With The Possibility Of Conclusion Within The Framework Of The So-called Open House Procedure. 2026-05-10
Germany Conclusion Of Non-exclusive Discount Agreements According To § 130a Para. 8 Sgb V For The Mentioned Active Ingredients With The Possibility Of Conclusion Within The Framework Of The So-called Open House Procedure. 2026-05-10
Germany Conclusion Of A Non-exclusive Discount Agreement In Accordance With Section 130a Paragraph 8 Sgb V For Medicines With The Active Ingredient Triptorelin (atc Code: L02ae04 And H01ca07). 2026-05-10
Germany Drug Discount Agreements From January 1st, 2026 On Various Active Ingredients As Part Of An Open House Procedure 2026-05-10
Germany Conclusion Of A Non-exclusive Discount Agreement In Accordance With Section 130a Paragraph 8 Sgb V For Medicines With The Active Ingredient Somatropin (atc Code: H01ac01). 2026-05-10
Germany Conclusion Of A Non-exclusive Discount Agreement In Accordance With Section 130a Paragraph 8 Sgb V For Drugs With The Active Ingredient Pazopanib (atc Code: L01ex03). 2026-05-10
Whats app